IGF1 and Alzheimer disease: It has been hypothesized that depletion of β-amyloid monomers, occurring in the preclinical phase of AD, might be the cause of early insulin/IGF-1 signaling disturbances that anticipate cognitive decline (Giuffrida et al., 2012).